【作者单位】Affiliations 1 Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang Province, 315211, China. 2 Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, 201203, China. 3 Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, Singapore, 117543, Singapore. 4 Medical College, Tibet University, Lhasa, 850011, China. 5 Department of Chemical Biology, College of Chemistry and Chemical Engineering, and The Key Laboratory for Chemical Biology of Fujian Province, Xiamen University, Xiamen, Fujian Province, 361005, China. 6 Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing, 102206, China. 7 Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang Province, 315211, China. chenyuzong@nbu.edu.cn. 8 Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, Singapore, 117543, Singapore. chenyuzong@nbu.edu.cn.
【年份】2022
【页码】1-9
【ISSN】1672-0415
【关键词】COVID-19 Chinese medicine comorbidity pathophysiology target therapeutic mechanism.
【摘要】 Objective: To investigate how the National Health Commission of China -recommended Chinese medicines modulate the major maladjustments of coronavirus disease 2019 , particularly the clinically observed complications and comorbidities. Methods: By fo...
